Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways

Figure 8 Naringenin prevents elevation of metalloproteinase-9 and 2 activities in CCl₄-treated rats. Matrix metalloproteinase (MMP)-9 (A) and MMP-2 (B) activities was analyzed by zymography using gelatin-substrate gels (C). Liver samples for control rats, carbon tetrachloride (CCl₄)-treated rats, CCl₄ plus naringenin rats (CCl₄ + NAR), and rats administered with NAR alone (NAR) were analyzed. Values are expressed as average of relative IOD, normalized to the control group values (control = 1). Each bar represents the mean value of three rats ± SE. ^aP < 0.05 vs control group; ^bP < 0.05 vs CCl₄ group.